{"id":"mrna","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL5315014","moleculeType":"Unknown"},"_dailymed":{"setId":"48c86164-de07-4041-b9dc-f2b5744714e5","title":"COMIRNATY (COVID-19 VACCINE, MRNA) INJECTION, SUSPENSION [PFIZER LABORATORIES DIV PFIZER INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"mRNA drugs encode instructions for cells to synthesize specific proteins that either replace deficient proteins, provide enzymatic function, or stimulate the immune system to recognize and attack disease targets. The mRNA is typically encapsulated in lipid nanoparticles for cellular delivery and translation into functional proteins.","oneSentence":"mRNA-based therapeutics deliver genetic instructions to cells to produce therapeutic proteins or trigger immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T06:16:37.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Personalized cancer vaccines (investigational)"},{"name":"Infectious disease vaccines (investigational)"}]},"trialDetails":[{"nctId":"NCT06585241","phase":"PHASE4","title":"A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-09","conditions":"SARS-CoV-2","enrollment":1144},{"nctId":"NCT02243592","phase":"","title":"Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-24","conditions":"Malignant Neoplasm","enrollment":170},{"nctId":"NCT07197450","phase":"EARLY_PHASE1","title":"Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-20","conditions":"Hypoparathyroidism","enrollment":6},{"nctId":"NCT07495215","phase":"PHASE1, PHASE2","title":"A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection","status":"RECRUITING","sponsor":"Yinghua Xu","startDate":"2025-09-11","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":20},{"nctId":"NCT06332677","phase":"NA","title":"Target of Suv420h1/2 in Hepatocytes","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2023-03-01","conditions":"NAFLD","enrollment":260},{"nctId":"NCT07204964","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-07","conditions":"Influenza, Human","enrollment":971},{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT05668741","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-02-27","conditions":"Cystic Fibrosis","enrollment":39},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT07492316","phase":"PHASE1","title":"RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)","status":"NOT_YET_RECRUITING","sponsor":"University of Florida","startDate":"2026-05-15","conditions":"Recurrent Medulloblastoma","enrollment":24},{"nctId":"NCT07053982","phase":"NA","title":"Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2026-03-23","conditions":"Endometriosis","enrollment":20},{"nctId":"NCT07492966","phase":"","title":"Exosomes Effect on Visual Function in CVI","status":"COMPLETED","sponsor":"Hatice Semrin Timlioglu İper","startDate":"2024-06-30","conditions":"Cortical Visual Impairment, Visual Function","enrollment":32},{"nctId":"NCT04534205","phase":"PHASE2, PHASE3","title":"A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2021-01-07","conditions":"Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer","enrollment":350},{"nctId":"NCT06805305","phase":"PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2025-03-17","conditions":"Glioblastoma (GBM)","enrollment":180},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT06799247","phase":"PHASE3","title":"Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis","status":"RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2025-05-06","conditions":"Myasthaenia Gravis","enrollment":100},{"nctId":"NCT06747156","phase":"EARLY_PHASE1","title":"A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-23","conditions":"Autoimmune Diseases","enrollment":66},{"nctId":"NCT05392075","phase":"","title":"COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-03-15","conditions":"COVID-19 Pneumonia, COVID-19","enrollment":100},{"nctId":"NCT05130437","phase":"PHASE1, PHASE2","title":"A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2021-11-09","conditions":"Propionic Acidemia","enrollment":50},{"nctId":"NCT07128615","phase":"PHASE1, PHASE2","title":"A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-04","conditions":"Influenza A","enrollment":405},{"nctId":"NCT05283902","phase":"","title":"Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly","status":"COMPLETED","sponsor":"Federal University of Espirito Santo","startDate":"2022-03-19","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases","enrollment":260},{"nctId":"NCT05996731","phase":"NA","title":"Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases","status":"RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2024-02-21","conditions":"Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, Autosomal Dominant Polycystic Kidney","enrollment":105},{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT07485543","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-03","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT04649021","phase":"PHASE2","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-12-04","conditions":"SARS-CoV-2","enrollment":960},{"nctId":"NCT00001888","phase":"","title":"Sample Collections From the Airways of Asthmatic Patients","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-06-02","conditions":"Asthma","enrollment":574},{"nctId":"NCT06309485","phase":"PHASE2","title":"Phase 2 Study of WGI-0301 for Advanced HCC","status":"RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","startDate":"2024-07-31","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":60},{"nctId":"NCT04573140","phase":"PHASE1","title":"A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2021-12-13","conditions":"Adult Glioblastoma, High Grade Glioma, WHO Grade III or IV Malignant Glioma","enrollment":28},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT07473986","phase":"","title":"REAl LIfe\" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-07-08","conditions":"SARS-CoV-2 Omicron Variants","enrollment":88},{"nctId":"NCT05683457","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-04-05","conditions":"Cytomegalovirus Infection","enrollment":224},{"nctId":"NCT05189925","phase":"PHASE1","title":"NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-22","conditions":"Chronic Granulomatous Disease, Infection","enrollment":25},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT07391605","phase":"PHASE2","title":"Descartes-08 in Autoantibody Myositis","status":"NOT_YET_RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2026-03-01","conditions":"Antisynthetase Syndrome","enrollment":60},{"nctId":"NCT05446740","phase":"PHASE1","title":"A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-08-09","conditions":"Influenza, Human","enrollment":324},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT05660408","phase":"PHASE1, PHASE2","title":"RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-12","conditions":"Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma","enrollment":36},{"nctId":"NCT06389591","phase":"PHASE1","title":"RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2024-12-02","conditions":"Recurrent Glioblastoma","enrollment":24},{"nctId":"NCT04837547","phase":"PHASE1","title":"PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2021-09-20","conditions":"Neuroblastoma, Diffuse Intrinsic Pontine Glioma","enrollment":24},{"nctId":"NCT07444580","phase":"PHASE1","title":"PrP-targeting siRNA Safety & Mechanism Study","status":"NOT_YET_RECRUITING","sponsor":"Broad Institute of MIT and Harvard","startDate":"2026-04","conditions":"Prion Disease","enrollment":30},{"nctId":"NCT07455617","phase":"PHASE1","title":"Study of ABO2102 in KRAS-Mutated Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Abogen Biosciences Co., Ltd.","startDate":"2026-02","conditions":"Advanced / Metastatic Solid Tumor","enrollment":101},{"nctId":"NCT07408336","phase":"EARLY_PHASE1","title":"Clinical Study of AFN50 Injection in the Autoimmune Diseases","status":"RECRUITING","sponsor":"AlphaNa Bioscience Company Limited","startDate":"2026-02-04","conditions":"Autoimmune Diseases","enrollment":18},{"nctId":"NCT05672355","phase":"PHASE2","title":"A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"Chronic Lymphocytic Leukemia, COVID-19 Infection","enrollment":80},{"nctId":"NCT07051031","phase":"PHASE4","title":"COVID-19 Reactogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcel Curlin","startDate":"2025-10-01","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT07379580","phase":"PHASE2","title":"A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2026-02-20","conditions":"Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection","enrollment":310},{"nctId":"NCT07432867","phase":"PHASE1, PHASE2","title":"Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-02-25","conditions":"Sickle Cell Disease","enrollment":15},{"nctId":"NCT07447544","phase":"NA","title":"Predictive Factors for CNS Metastases in Early Breast Cancer Using Liquid Biopsy (AKRA CŽS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Oncology Ljubljana","startDate":"2025-07-07","conditions":"Breast Cancer, Central Nervous System Metastases","enrollment":22},{"nctId":"NCT07298200","phase":"PHASE1","title":"Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric Cancer","status":"RECRUITING","sponsor":"Jia Wei","startDate":"2025-12-26","conditions":"Advanced Gastric Cancer","enrollment":18},{"nctId":"NCT05415267","phase":"PHASE3","title":"Immunosuppression and COVID-19 Boosters","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2023-07-21","conditions":"COVID-19","enrollment":320},{"nctId":"NCT07288112","phase":"PHASE1, PHASE2","title":"DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma","status":"RECRUITING","sponsor":"Diakonos Oncology Corporation","startDate":"2026-02-23","conditions":"Refractory Melanoma","enrollment":35},{"nctId":"NCT06694753","phase":"PHASE1","title":"Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.","status":"RECRUITING","sponsor":"International AIDS Vaccine Initiative","startDate":"2025-12-15","conditions":"HIV Infections","enrollment":96},{"nctId":"NCT07334119","phase":"PHASE1","title":"Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors","status":"RECRUITING","sponsor":"Myeloid Therapeutics","startDate":"2025-11-25","conditions":"HER2-Expressing Solid Tumors","enrollment":60},{"nctId":"NCT06118086","phase":"PHASE1, PHASE2","title":"Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma","status":"RECRUITING","sponsor":"Remix Therapeutics","startDate":"2023-12-20","conditions":"Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma","enrollment":100},{"nctId":"NCT05938387","phase":"PHASE1","title":"Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma","status":"COMPLETED","sponsor":"CureVac","startDate":"2023-06-01","conditions":"Glioblastoma","enrollment":37},{"nctId":"NCT01558804","phase":"","title":"GRoup A StrePtococcus","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2011-05-09","conditions":"Streptococcal Pharyngitis","enrollment":180},{"nctId":"NCT07418229","phase":"PHASE1","title":"Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-03-09","conditions":"RSV, mRNA Vaccine","enrollment":60},{"nctId":"NCT06353646","phase":"NA","title":"XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer","status":"RECRUITING","sponsor":"Wu Wenming","startDate":"2024-03-12","conditions":"Pancreatic Cancer","enrollment":28},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT05799612","phase":"PHASE1","title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-22","conditions":"Angiosarcoma","enrollment":""},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT07329894","phase":"PHASE1","title":"Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2026-02","conditions":"Gastrointestinal Cancer","enrollment":18},{"nctId":"NCT04977024","phase":"PHASE2","title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GeoVax, Inc.","startDate":"2021-09-27","conditions":"COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia","enrollment":63},{"nctId":"NCT07222384","phase":"PHASE3","title":"A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":343},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT07390968","phase":"PHASE2","title":"Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-09-01","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":56},{"nctId":"NCT05119855","phase":"PHASE3","title":"Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-28","conditions":"Papillomavirus Infections, Coronavirus Disease (COVID-19)","enrollment":165},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06143046","phase":"PHASE2","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-11-15","conditions":"Respiratory Syncytial Virus","enrollment":360},{"nctId":"NCT06382311","phase":"PHASE1, PHASE2","title":"A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-18","conditions":"Influenza, Human","enrollment":991},{"nctId":"NCT07388212","phase":"EARLY_PHASE1","title":"Exploratory Study on LNP-mRNA Drugs Targeting CD19/BCMA for the Treatment of Relapsed and Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-23","conditions":"Autoimmune Diseases","enrollment":27},{"nctId":"NCT07368803","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection","status":"RECRUITING","sponsor":"Yifan Wang","startDate":"2025-09-11","conditions":"Biliary Malignant Tumors","enrollment":20},{"nctId":"NCT04975893","phase":"PHASE2","title":"A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-06-18","conditions":"Cytomegalovirus Infection","enrollment":135},{"nctId":"NCT06873334","phase":"PHASE2, PHASE3","title":"Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease","status":"RECRUITING","sponsor":"Skyhawk Therapeutics, Inc.","startDate":"2025-05-27","conditions":"Huntington Disease, Huntingtons Disease","enrollment":120},{"nctId":"NCT07117487","phase":"PHASE3","title":"A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-08-05","conditions":"Respiratory Syncytial Virus","enrollment":507},{"nctId":"NCT07019883","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-06-12","conditions":"Avian Influenza","enrollment":80},{"nctId":"NCT07378644","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease","status":"RECRUITING","sponsor":"Skyhawk Therapeutics, Inc.","startDate":"2026-01-06","conditions":"Huntington Disease","enrollment":400},{"nctId":"NCT06602531","phase":"PHASE1","title":"Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-12-10","conditions":"Influenza, Human","enrollment":212},{"nctId":"NCT06065176","phase":"PHASE4","title":"The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection","status":"COMPLETED","sponsor":"Sarang K. Yoon, DO, MOH","startDate":"2023-11-22","conditions":"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection","enrollment":1188},{"nctId":"NCT06789653","phase":"","title":"A Novel Approach Utilizing Organ Specific Age Proteomics","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-10-10","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT05951920","phase":"NA","title":"Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT07363369","phase":"PHASE1","title":"Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01-25","conditions":"Advanced Malignant Solid Tumors","enrollment":10},{"nctId":"NCT07362602","phase":"EARLY_PHASE1","title":"Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army","startDate":"2026-01-26","conditions":"Hematological Malignancies","enrollment":47},{"nctId":"NCT07362758","phase":"EARLY_PHASE1","title":"Exploratory Study on mRNA Therapy Targeting CD19 for the Treatment of Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2026-01-01","conditions":"Autoimmune Diseases","enrollment":47},{"nctId":"NCT04159103","phase":"PHASE1, PHASE2","title":"Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2021-04-15","conditions":"Propionic Acidemia","enrollment":77},{"nctId":"NCT07185399","phase":"PHASE4","title":"Systems Biological Analysis of Immune Responses to RSV Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2025-10-13","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":14},{"nctId":"NCT05264974","phase":"PHASE1","title":"Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization","status":"RECRUITING","sponsor":"University of Florida","startDate":"2026-02","conditions":"Melanoma, Soft Tissue Sarcoma","enrollment":18},{"nctId":"NCT06727058","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-09","conditions":"Influenza Immunization","enrollment":276},{"nctId":"NCT07354659","phase":"PHASE2","title":"Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2026-01-10","conditions":"Herpes Zoster","enrollment":800},{"nctId":"NCT07349836","phase":"EARLY_PHASE1","title":"Application of mRNA Immunotherapy Technology in EB Virus Related Diseases","status":"NOT_YET_RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2026-01-10","conditions":"EBV-associated Tumors","enrollment":40},{"nctId":"NCT06655870","phase":"PHASE1","title":"A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-10-31","conditions":"Healthy Participants","enrollment":52},{"nctId":"NCT07349823","phase":"EARLY_PHASE1","title":"Exploratory Study on the Treatment of Relapsed and Refractory Immune Related Diseases With WGb-0301 Injection","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01-26","conditions":"Autoimmune Diseases","enrollment":47},{"nctId":"NCT07240896","phase":"EARLY_PHASE1","title":"A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)","status":"RECRUITING","sponsor":"DSciLab Co., Ltd.","startDate":"2025-12-31","conditions":"Wilsons Disease","enrollment":18},{"nctId":"NCT04899310","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2021-08-06","conditions":"Methylmalonic Acidemia","enrollment":74},{"nctId":"NCT07349849","phase":"EARLY_PHASE1","title":"Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies","status":"RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2025-12-20","conditions":"B-cell Malignancies","enrollment":47},{"nctId":"NCT04733534","phase":"PHASE2","title":"An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-06-06","conditions":"Frailty, Childhood Cancer","enrollment":110},{"nctId":"NCT06496451","phase":"","title":"Measurement of Frataxin mRNA in Biofluids","status":"COMPLETED","sponsor":"University of Florida","startDate":"2024-08-08","conditions":"Friedreich Ataxia","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":624734,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"mRNA","genericName":"mRNA","companyName":"University Hospital Tuebingen","companyId":"university-hospital-tuebingen","modality":"Biologic","firstApprovalDate":"","aiSummary":"mRNA-based therapeutics deliver genetic instructions to cells to produce therapeutic proteins or trigger immune responses. Used for Personalized cancer vaccines (investigational), Infectious disease vaccines (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}